作者: Nikolaos G. Almyroudis , Minoo Battiwalla , Brahm H. Segal
DOI: 10.1007/978-1-59745-415-5_9
关键词: Clinical trial 、 Immunology 、 Unmet needs 、 Immune system 、 Adoptive cell transfer 、 Immunity 、 Colony-stimulating factor 、 Hematopoietic stem cell 、 Medicine 、 Cellular immunity
摘要: Patients with hematologic malignancies and hematopoietic stem cell transplant recipients have a broad range of immune deficits that predispose to common opportunistic infectious diseases. Infectious complications are major cause morbidity mortality in these patients. Effective augmentation strategies used as prophylaxis adjunctive therapy represent an important unmet need. We discuss several immune-based tailored specific patient populations. These include augment neutrophil number, enhance function neutrophils macrophages, passive antibody therapy, cellular immunity. evaluate therapies currently available the evidence supporting their use. There is large “pipeline” novel promising immunotherapies at preclinical early stages clinical development. innate antigen-specific immunity by stimulating pathogen recognition pathways, adoptive transfer immunity, vaccine review more cutting-edge approaches, emphasis on fungal viral infections. gaps knowledge challenges bringing trials.